Table 1.
Clinical characteristics of patients with malignant pheochromocytoma or paraganglioma treated with CVD chemotherapy
| All | Respondersa | Non-respondersb with stable disease | Non-respondersb with progressive disease | |
|---|---|---|---|---|
| Number of patients | 17 | 8 | 4 | 5 |
| Age (year) | 54.6 ± 12.6 | 50.1 ± 13.8 | 57.5 ± 11.7 | 59.4 ± 11.3 |
| Age at the diagnosis of PPGL (year) | 41.3 ± 17.6 | 31.9 ± 17.4 | 44.0 ± 17.3 | 50.8 ± 14.0c |
| Age at the diagnosis of malignant disease (year) | 47.3 ± 15.1 | 43.1 ± 14.8 | 48.5 ± 17.8 | 52.2 ± 15.0 |
| Sex; M/F | 11/6 | 5/3 | 2/2 | 2/3 |
| Localization of primary tumor | ||||
| Right or left adrenal gland | 4 | 1 | 2 | 1 |
| Peri-adrenal | 6 | 2 | 0 | 4 |
| Paraaortic | 4 | 3 | 1 | 0 |
| Urinary bladder | 2 | 1 | 1 | 0 |
| Heart | 1 | 1 | 0 | 0 |
| Duration of the disease prior to initiation of CVD chemotherapy (year) | 9.1 ± 8.1 | 12.8 ± 9.6 | 5.8 ± 5.0 | 5.8 ± 5.4c |
| Time interval between the diagnosis of PPGL and detection of malignant disease (year) | 6.5 ± 8.4 | 12.3 ± 10.1 | 4.5 ± 5.3 | 1.4 ± 1.3c |
Data shown as mean ± standard deviation
CVD cyclophosphamide, vincristine, dacarbazine; PPGL pheochromocytoma or paraganglioma
aResponders; patients with either any biochemical responses and/or any tumor responses
bNon-responders; patients with no clinically significant biochemical or tumor responses
c P < 0.05 vs. responders